Table 2.
Correlation between AZT treatment response and p53 status in ATL patients
| Diagnosis | p53 status before initiation of AZT treatment | Patient response to AZT treatment | p53 status after AZT treatment | p53 transcriptional activity | |
|---|---|---|---|---|---|
| ATL1 | Acute | Mut E198G | NR | NA | No |
| ATL2 | Acute | Frameshift, stop aa 148 | NR | NA | No |
| ATL3 | Acute | Mut Q192R | PR | Q192R | Partial |
| ATL4 | Chronic | wt | R | R273H | No |
| ATL5 | Chronic | wt | CR | wt | Yes |
| ATL6 | Smoldering | wt | CR | NA | Yes |
| ATL7 | Lymphoma | Mut P222L; I 232T | NR | NA | No |
| ATL8 | Acute | wt | PR | NA | Yes |
| ATL9 | Acute | wt | PR | NA | Yes |
| ATL10 | Lymphoma | mut | NR | NA | ND |
| ATL11 | Lymphoma | mut | NR | NA | ND |
| ATL12 | Acute | mut | NR | NA | ND |
| ATL13 | Acute | Mut R72P;S166P;R280G | NR | NA | No |
| ATL14 | Chronic | Mut R72P;H178Y;I255V | NR | NA | No |
Status of patients before AZT treatment, response to treatment, and status of p53 gene and its transcriptional activity. The criteria for clinical therapeutic response were as follows: complete remission was defined as the disappearance of all measurable and assessable disease, lasting more than 3 months; partial remission was defined as reduction of leukemic cell count, lasting more than 1 month but less than 3 months; and not responding was defined as increase in leukemic cell count. CR indicates complete remission; PR, partial remission; NR, not responding; R, relapse; NA, not available; and ND, not determined.